Oral Mucositis Clinical Trial
Official title:
Effect of Ascorbic Acid Oral Supplementation in Assessing the Severity of Oral Mucositis in Chemo-radiation Therapy of Head and Neck Cancers.
The surrounding controversies both advocating and simultaneously opposing the use of vitamin
C, mostly extrapolating animal models to human models, it has not been used individually to
assess the severity of oral mucositis during chemoradiotherapy.
The present study is undertaken to evaluate the effect of vitamin C oral supplements in
assessing the severity of oral mucositis during chemoradiotherapy for oral cancer.
Oral mucositis is a predictable and unavoidable representation during the course of
radiotherapy employed for treatment of head and neck cancers. The term oral mucositis is used
to describe inflammation of the oral mucosa, a separate entity distinct from oral lesions
with other pathogenic background generally summarized as stomatitis. The cells that line the
gastrointestinal tract from the mouth to the rectum are especially vulnerable to such
changes. The incidence and severity of oral mucositis is influenced by the type of
antineoplastic treatment administered and patient related factors. The pathogenesis of
radiation mucositis though not completely understood, is usually either by direct DNA damage
or via an indirect mechanism of releasing free radicals upon radiolysis of water effecting
the oral epithelium.It is associated with significant morbidity, pain, odynophagia,
malnutrition thereby affecting the overall quality of life in these patients and carrying a
more important risk of systemic infections particularly in impaired host defense setup.In
addition to acute damage wide range of GI mucosal involvement occurs during radiotherapy.
Various radiation modifying agents have been used which can either selectively protect normal
cells but not tumor cells against therapeutic damage or can selectively enhance the effect of
radiation on tumor cells but not on normal cells thereby improving efficacy of radiation
therapy. In spite of extensive research most of them are found to be toxic.
Antioxidants represent most selective radiation modifying agents that are non toxic to
humans. However, because of many conflicting hypothesis on their usage affecting tumor
response and also decreasing the radiation induced toxicity on normal cells, recommendations
have followed for their non usage during chemo-radiotherapy. In spite of such reservations on
behalf of oncologists over 70% of patients are on antioxidant supplements such as those
containing vitamin A, vitamin C and polar carotenoids with or without the knowledge of
oncologists.
Antioxidants can neutralize those free radicals generated during radio-chemo therapy
enhancing body's antioxidant stores in order to prevent mucositis and to maintain healthy
oral tissues. Literature survey provides exhaustive list of such antioxidants successfully
implicated in controlling oral mucositis to some extent. Antioxidants such as beta carotene,
vitamin E and vitamin C in combination, glutamine, glutathione have been studied.
Vitamin C is a water soluble nutrient that has wide antioxidant and wound healing properties.
It has been widely in scurvy patients but its effect on conventional cancer therapy by
radiation and chemotherapy were little known. Limited preclinical data suggested that this
vitamin at high concentrations increased the toxicity of certain chemotherapeutic drugs in
animals.
Recommended daily allowance (RDA) for vitamin C is 90mgper day for men and 75mg per day for
women, upper limit being 2000mg per day. Evidence points out that the intake to achieve
therapeutic tissue concentration in normal people should be several times higher than RDA.
Conversely a recent study implicated dangers of consuming high doses of vitamin C which may
turn from antioxidant to pro oxidant interfering radiotherapy. However it should be noted
that the conditions used in the above study prevailed were invitro in nature, which cannot
reflect an identical situation invivo. Few other studies believed that it can enhance immune
function by increasing natural killer cells and lymphocyte activity.
With such controversial background and paucity of data in human intervention, this study is
undertaken to evaluate the effect of vitamin c in assessing the severity of oral mucositis in
patients undergoing cancer chemo and radiotherapy concurrently
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02229136 -
Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus
|
Phase 2 | |
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Enrolling by invitation |
NCT02662374 -
Oral Hygiene Regimen in Patients on HCT
|
Phase 4 | |
Completed |
NCT00938080 -
Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
|
Phase 1 | |
Completed |
NCT00756951 -
Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Patients Receiving Chemoradiation Therapy for Head and Neck Cancer
|
Phase 2 | |
Completed |
NCT00701688 -
Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 1 | |
Not yet recruiting |
NCT05059613 -
Thalidomide With or Without Probiotics in Radioactive Oral Mucositis
|
N/A | |
Completed |
NCT04440930 -
White Tea for Prevention of Chemotherapy Induced Mucositis
|
N/A | |
Completed |
NCT05705622 -
The Effect of Nursing Education on Oral Mucositis in Bone Marrow Transplant Patients
|
N/A | |
Completed |
NCT02399228 -
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Oral Mucositis
|
Phase 2 | |
Withdrawn |
NCT02589860 -
Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant
|
||
Active, not recruiting |
NCT01772706 -
Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer
|
N/A | |
Enrolling by invitation |
NCT06122636 -
Efficacy of a Probiotic and Microbiological Analysis on Oral Complications Induced by Antineoplastic Therapies in Patients With HNC
|
N/A | |
Completed |
NCT03689712 -
ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients
|
Phase 3 | |
Terminated |
NCT02539342 -
Caphosol Study: Prevention of Oral Mucositis in Children, Adolescents and Young Adults Receiving Chemotherapy
|
Phase 3 | |
Completed |
NCT02555501 -
Oral Mucositis and Laser Therapy Associated With Photodynamic Therapy
|
Phase 3 | |
Completed |
NCT01789658 -
Cryotherapy for Prevention of Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT00790322 -
Efficacy and Safety Study of SBG vs Placebo in Head and Neck Cancer Patients Undergoing Radiation Therapy
|
Phase 3 | |
Recruiting |
NCT00549952 -
Observational Study of Anti-Cancer Therapy Induced Oral Mucositis in Korean Cancer Patients
|
N/A | |
Completed |
NCT00289003 -
The Protective Effect of Soluble Beta-1,3/1,6-Glucan Compared to Placebo in Oral Mucositis in Head and Neck Cancer Patients
|
Phase 2 |